ASH Voice of China| Professor Xian Zhang: High Efficacy And Safety of Nanobody Based Anti-BCMA CAR-T Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma.
The 65th Annual Meeting of the American Society of Hematology (ASH) was held from 9 to 12 December 2023, in San Diego, USA. As the world's largest and most comprehensive hematology top academic event, it attracts thousands of experts and scholars from all over the world every year to share the most cutting-edge hematology advances and groundbreaking clinical data. At this year's ASH Congress, a study by Professor Xian Zhang of Lu Dao Pei Hospital was selected for oral presentation (Abstract No. 2107), which investigated the high efficacy and safety of nanobody based anti-BCMA CAR-T therapy in treating patients with relapsed or refractory multiple myeloma.